Blueprint Medicines was founded in 2008 and operates in Wilmington, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100).

JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a ...

In 2023, the FDA approved Blueprint Medicines’ Ayvakit (avapritinib) as the first, only treatment for indolent systemic ...